Affiliation: Osaka National Hospital
- Poorly differentiated endocrine carcinoma of the pancreas responded to gemcitabine: Case reportShoichi Nakazuru
Department of Gastroenterology and Hepatology, National Hospital Organization, Osaka National Hospital, Chuo Ku, Osaka City, Osaka 540 0006, Japan
World J Gastroenterol 16:3853-6. 2010..Gemcitabine could be an effective treatment option for pancreatic PDEC that is resistant to other treatments...
- [Case of primary hepatic neuroendocrine carcinoma diagnosed by needle biopsy]Hiroko Hasegawa
Department of Gastroenterology and Hepatology, National Hospital Organization, Osaka National Hospital, Japan
Nihon Shokakibyo Gakkai Zasshi 107:1956-62. 2010..Serum levels of NSE and the tumor size were decreased after the first course of CTX. We here report a case of primary hepatic neuroendocrine carcinoma treated with CTX following the diagnosis by the needle biopsy...
- [Synchronous double cancer of the gallbladder and rectum successfully treated with S-1 as second-line chemotherapy- a case report]Manabu Araki
Dept of Gastroenterology and Hepatology, Osaka National Hospital, Japan
Gan To Kagaku Ryoho 38:1857-9. 2011..He survived for 17 months after the first course of chemotherapy, and the progression-free survival with S-1 was 10 months. Therefore, S-1 could be an effective agent for synchronous double cancer of the gallbladder and rectum...
- Optimal treatment change criteria for advanced gastric cancer with non-measurable peritoneal metastasis: symptom/tumor marker-based versus CT-basedHiroko Hasegawa
Department of Gastroenterology, Osaka National Hospital, Osaka, Japan
Anticancer Res 34:5169-74. 2014..We attempted to clarify which criterion for treatment change contributes more to longer survival...
- Optimal indications for second-line chemotherapy in advanced gastric cancerHiroko Hasegawa
Departments of Gastroenterology, Osaka National Hospital, Osaka, Japan
Anticancer Drugs 23:465-70. 2012..5 g/dl at initiation of second-line chemotherapy and time to progression less than 170 days on first-line chemotherapy...